中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2014年
8期
626-629
,共4页
培美曲塞%营养支持治疗%非小细胞肺癌
培美麯塞%營養支持治療%非小細胞肺癌
배미곡새%영양지지치료%비소세포폐암
Pemetrexed%Supportive care%Non-small cell lung cancer
背景与目的：肺癌是目前发病率最高的恶性肿瘤之一，肺癌中以非小细胞肺癌(non-small cell lung cancer，NSCLC)为主，化疗在晚期NSCLC中占主要地位，但对于老年晚期NSCLC的化疗目前存在争议。本研究旨在比较培美曲塞与最佳营养支持治疗在ECOG=2分且年龄≥70岁晚期NSCLC患者的临床疗效，并探讨培美曲塞的不良反应。方法：以84例ECOG=2分且年龄≥70岁的晚期NSCLC患者为研究对象，随机分为培美曲塞组(治疗组)和最佳营养支持治疗组(对照组)(n=42)。治疗组采用培美曲塞二钠，500 mg/m2，第1天，静脉滴注，3周为1个周期。对照组每天保证200 g葡萄糖供应，蛋白质根据患者体质量供给。近期疗效治疗组2个周期后评价，对照组2个月后评价。结果：治疗组完全缓解(CR)0例，部分缓解(PR)6例(14.3%)，病情稳定(SD)21例(50.0%)，病情进展(PD)13例(30.9%)，客观有效率14.3%，疾病控制率64.3%。对照组CR 0例，PR 1例(2.4%)，SD 15例(35.7%)，PD 25例(60.9%)，1例死亡，客观有效率为2.4%，疾病控制率为39.0%(P<0.05)。结论：培美曲塞在ECOG=2分且年龄≥70岁晚期NSCLC患者的疗效优于最佳营养支持治疗，并且不良反应轻，患者可以耐受。
揹景與目的：肺癌是目前髮病率最高的噁性腫瘤之一，肺癌中以非小細胞肺癌(non-small cell lung cancer，NSCLC)為主，化療在晚期NSCLC中佔主要地位，但對于老年晚期NSCLC的化療目前存在爭議。本研究旨在比較培美麯塞與最佳營養支持治療在ECOG=2分且年齡≥70歲晚期NSCLC患者的臨床療效，併探討培美麯塞的不良反應。方法：以84例ECOG=2分且年齡≥70歲的晚期NSCLC患者為研究對象，隨機分為培美麯塞組(治療組)和最佳營養支持治療組(對照組)(n=42)。治療組採用培美麯塞二鈉，500 mg/m2，第1天，靜脈滴註，3週為1箇週期。對照組每天保證200 g葡萄糖供應，蛋白質根據患者體質量供給。近期療效治療組2箇週期後評價，對照組2箇月後評價。結果：治療組完全緩解(CR)0例，部分緩解(PR)6例(14.3%)，病情穩定(SD)21例(50.0%)，病情進展(PD)13例(30.9%)，客觀有效率14.3%，疾病控製率64.3%。對照組CR 0例，PR 1例(2.4%)，SD 15例(35.7%)，PD 25例(60.9%)，1例死亡，客觀有效率為2.4%，疾病控製率為39.0%(P<0.05)。結論：培美麯塞在ECOG=2分且年齡≥70歲晚期NSCLC患者的療效優于最佳營養支持治療，併且不良反應輕，患者可以耐受。
배경여목적：폐암시목전발병솔최고적악성종류지일，폐암중이비소세포폐암(non-small cell lung cancer，NSCLC)위주，화료재만기NSCLC중점주요지위，단대우노년만기NSCLC적화료목전존재쟁의。본연구지재비교배미곡새여최가영양지지치료재ECOG=2분차년령≥70세만기NSCLC환자적림상료효，병탐토배미곡새적불량반응。방법：이84례ECOG=2분차년령≥70세적만기NSCLC환자위연구대상，수궤분위배미곡새조(치료조)화최가영양지지치료조(대조조)(n=42)。치료조채용배미곡새이납，500 mg/m2，제1천，정맥적주，3주위1개주기。대조조매천보증200 g포도당공응，단백질근거환자체질량공급。근기료효치료조2개주기후평개，대조조2개월후평개。결과：치료조완전완해(CR)0례，부분완해(PR)6례(14.3%)，병정은정(SD)21례(50.0%)，병정진전(PD)13례(30.9%)，객관유효솔14.3%，질병공제솔64.3%。대조조CR 0례，PR 1례(2.4%)，SD 15례(35.7%)，PD 25례(60.9%)，1례사망，객관유효솔위2.4%，질병공제솔위39.0%(P<0.05)。결론：배미곡새재ECOG=2분차년령≥70세만기NSCLC환자적료효우우최가영양지지치료，병차불량반응경，환자가이내수。
Background and purpose:Lung cancer is the one with the highest incidence tumors, is mainly appeared to be non-small cell lung cancer(NSCLC). The main treatment method is chemotherapy. However, it is controversial whether using chemotherapy in the patients of advanced NSCLC. The present study aimed to observe the efifcacy and toxicity of pemetrexed contrast to the best supportive care in the NSCLC patients of ECOG=2 and older than 70.Methods:A total number of 84 patients of ECOG=2 and older than 70 with advanced NSCLC were randomly assigned into two groups. The study group accepted pemetrexed, 500 mg/m2,every 3 weeks as a cycle, and the control group was given 200 g glucose supply and protein according to patients’ weight every day. Evaluation of the study group was performed at end of 2 cycles and the control group was evaluated after 2 months.Results:There was no CR patient in 2 groups. In the study group there were 6 patients of PR (14.3%), 21 patients of SD (50%) and 13 patients of PD (30.9%), the effective rate was 14.3%, and the disease control rate was 64.3%. There were 1 patient of PR (2.4%), 15 patients of SD (35.7%), 25 patients of PD (60.9%), 1 patient of death, the effective rate was 2.4% and the disease control rate was 39.0% in the control group (P<0.05).Conclusion:The study group has better treatment effect and adverse reaction in patients of ECOG=2 and older than 70 with advanced non-small-cell lung cancer and the toxicity could be tolerated.
